Your browser doesn't support javascript.
loading
Selective carbonic anhydrase IX and XII inhibitors based around a functionalized coumarin scaffold.
Huwaimel, Bader I; Jonnalagadda, Sravan K; Jonnalagadda, Shirisha; Kumari, Shikha; Nocentini, Alessio; Supuran, Claudiu T; Trippier, Paul C.
Afiliación
  • Huwaimel BI; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Jonnalagadda SK; Department of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
  • Jonnalagadda S; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Kumari S; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Nocentini A; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Supuran CT; Polo Scientifico, Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy.
  • Trippier PC; Polo Scientifico, Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy.
Drug Dev Res ; 84(4): 681-702, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36872587
ABSTRACT
Inhibition of specific carbonic anhydrase (CA) enzymes is a validated strategy for the development of agents to target cancer. The CA isoforms IX and XII are overexpressed in various human solid tumors wherein they play a critical role in regulating extracellular tumor acidification, proliferation, and progression. A series of novel sulfonamides based on the coumarin scaffold were designed, synthesized and characterized as potent and selective CA inhibitors. Selected compounds show significant activity and selectivity over CA I and CA II to target the tumor-associated CA IX and CA XII with high inhibition activity at the single digit nanomolar level. Twelve compounds were identified to be more potent compared with acetazolamide (AAZ) control to inhibit CA IX while one was also more potent than AAZ to inhibit CA XII. Compound 18f (Ki's = 955 nM, 515 nM, 21 nM and 5 nM for CA's I, II, IX, and XII, respectively) is highlighted as a novel CA IX and XII inhibitor for further development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cumarinas / Neoplasias Límite: Humans Idioma: En Revista: Drug Dev Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cumarinas / Neoplasias Límite: Humans Idioma: En Revista: Drug Dev Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos